Sort   by:  
 Page size 
UnknownLoss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study.
Not available
S-EPMC7731769 | biostudies-literature
UnknownTP53 drives abscopal effect by secretion of senescence-associated molecular signals in non-small cell lung cancer.
Not available
S-EPMC7934399 | biostudies-literature
UnknownRevised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.
Not available
S-EPMC4846284 | biostudies-literature
UnknownSafety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2- Advanced Breast Cancer: Results from the Italian Subpopulation of Phase 3b CompLEEment-1 Study.
Not available
S-EPMC9684264 | biostudies-literature
UnknownMITO39: Efficacy and Tolerability of Pegylated Liposomal Doxorubicin (PLD)-Trabectedin in the Treatment of Relapsed Ovarian Cancer after Maintenance Therapy with PARP Inhibitors-A Multicenter Italian Trial in Ovarian Cancer Observational Case-Control Study.
Not available
S-EPMC10778130 | biostudies-literature
UnknownThe prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial.
Not available
S-EPMC8253801 | biostudies-literature
UnknownDistinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting.
Not available
S-EPMC7027476 | biostudies-literature
Sort   by:  
 Page size